AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone. More: AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals Source: News
read moreThe National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS. More: NICE rules against first-line use of Ipsen’s Cabometyx Source: News
read moreClovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. More: EU filing for Clovis’ Rubraca in ovarian cancer
read moreBristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning. More: BMS’ Opdivo cuts risk of melanoma
read more© 1994 - 2026 B.M. Pharmaceuticals